Floatz logo

BUSULFANUM

Fanconi Anemia

Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2/3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Fanconi Anemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Porteus, Matthew, MD
Phase 2/3BBB
Fludarabine
Porteus, Matthew, MD
Phase 2/3BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
Nivestim
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BBB
Prednisone
Fred Hutchinson Cancer Center
Phase 2BB

View all 42 →

Same molecule, other indications

BUSULFANUM is also rated in:

myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
graft versus host diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →